Bone remodeling markers in the detection of bone metastases in prostate cancer

Piedra, Concepción de la; Castro-Errecaborde, Nilda-Adriana; Traba, M. L.; Méndez-Dávila, Cioly; García-Moreno, Carmen; Acuña, Lucrecia Rodríguez de; Rodríguez‐Molina, Jesús

doi:10.1016/s0009-8981(03)00081-0

Cited by 47 publications

(28 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Corresponding to the pattern of the bone markers in Fig. 1, however, not only the formation markers PINP and BAP [89,142,143] are elevated due to osteoblastic metastases typical for prostate carcinoma, but also the classical resorption markers ICTP, TRAP5b, CTX, and NTX [89,140,[142][143][144][145].…”

Section: Bone Markers In Diagnosticsmentioning

confidence: 70%

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Jung

Lein

2014

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

Section: Bone Markers In Diagnosticsmentioning

confidence: 70%

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Jung

Lein

2014

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

View full text Add to dashboard Cite

“…PINP and ICTP are products of collagen metabolism, and their increased serum concentrations typically reflect pathologic bone turnover in cancer metastases to bone (38,(47)(48)(49)(50)(51). MIC-1 and PSA are derived from malignant cells (52,53).…”

Section: Discussionmentioning

confidence: 99%

Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases

Selander¹,

Brown

Sequeiros³

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Macrophage-inhibitory cytokine-1 (MIC-1) is a divergent member of the transforming growth factor B superfamily. It is up-regulated by nonsteroidal anti-inflammatory drugs and is highly expressed in human prostate cancer leading to high serum MIC-1 concentrations with advanced disease. A role for MIC-1 has been implicated in the process of early bone formation, suggesting that it may also mediate sclerosis at the site of prostate cancer bone metastases. Consequently, the aim of this study was to retrospectively determine the relationship of serum MIC-1 concentration and other markers related to current and future prostate cancer bone metastasis in a cohort of 159 patients with prostate cancer. Serum markers included cross-linked carboxy-terminal telopeptide of type I collagen, prostate-specific antigen, and amino-terminal propeptide of type I procollagen (PINP). The mean values of all the biomarkers studied were significantly higher in patients with baseline bone metastases (BM+, n = 35), when compared with those without bone metastases (BMÀ, n = 124). In a multivariate logistic model, both MIC-1 and PINP independently predicted the presence of baseline bone metastasis. Based on receiver operator curve analysis, the best predictor for the presence of baseline bone metastasis was MIC-1, which was significantly better than carboxy-terminal telopeptide of type I collagen, prostatespecific antigen, and PINP. Patients who experienced bone relapse had significantly higher levels of baseline MIC-1 compared with patients who did not (1476.7 versus 988.4; P = 0.03). Current use of acetylsalicylic acid did not influence serum MIC-1 levels in this cohort. Although requiring validation prospectively, these results suggest that serum MIC-1 determination may be a valuable tool for the diagnosis of current and future bone metastases in patients with prostate cancer.

show abstract

“…Table 2. Demographic data of breast and prostate cancer patients stratified according to the severity of metastatic bone disease (i.e., Soloway score) Studies focusing on the use of aaCTX showed consistent elevation of the marker in prostate cancer patients with bone metastasis compared with healthy male controls (22) or cancer patient without bone metastasis (23). In contrast, only one study described significant elevation in hhCTX in male lung cancer patients with bone metastasis (9), but in light of our negative findings, it remains to be established whether this biomarker is a selective indicator of lung metastasis in bones of males.…”

Section: Discussionmentioning

confidence: 99%

The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients

Leeming

Koizumi

Byrjalsen

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

109

View full text Add to dashboard Cite

The present study was sought to assess the relative use of eight biomarkers for the detection of bone metastases in cancer forms frequently spreading to the skeleton. Participants were 161 patients with either breast, prostate, or lung cancer. The presence and extent of bone metastases was assessed by imaging techniques (computer tomography and/ or magnetic resonance imaging) and Technetium-99m scintigraphy. Serum or urinary level of the bone resorption markers (AACTX, BBCTX, NTX, and ICTP), formation marker (BSAP), and osteoclastogenesis markers (osteoprotegerin, RANKL, and TRAP5b) was measured by commercially available immunoassays. When assessed on a group basis, all biomarkers, except for osteoprotegerin and RANKL, were significantly elevated in patients compared with those without bone metastases (P < 0.05). Biomarkers had greater diagnostic value in breast and prostate cancer patients, yet AACTX, NTx, and ICTP were able to discriminate lung cancer patients with or without bone metastases (P < 0.05). Strong linear associations were seen between the extent of skeletal infiltration and levels of the different biomarkers, except for osteoprotegerin and RANKL. Furthermore, all biomarkers (except for osteoprotegerin and RANKL) were indicative at the early stage of skeletal involvement (one to five metastases). When expressing sensitivity as the percentage increase in biomarker level relative to patients without bone metastases, AACTX showed the largest relative increases at each stage of the metastatic disease. These results suggest that closer monitoring of cancer patients with serial measures of biomarkers might facilitate the timely diagnosis of skeletal metastases. (Cancer Epidemiol Biomarkers Prev 2006;15(1):32 -8)

show abstract

Bone remodeling markers in the detection of bone metastases in prostate cancer

Cited by 47 publications

References 21 publications

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

Serum Macrophage Inhibitory Cytokine-1 Concentrations Correlate with the Presence of Prostate Cancer Bone Metastases

The Relative Use of Eight Collagenous and Noncollagenous Markers for Diagnosis of Skeletal Metastases in Breast, Prostate, or Lung Cancer Patients

Contact Info

Product

Resources

About